Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-001 With or Without Pembrolizumab in Advanced Solid Tumors
NCT07231458Phase 1Recruiting
- Sponsor
- Abalos Therapeutics
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label trial of ABX-001 in solid tumor (advanced stage) (2 arms), sponsored by Abalos Therapeutics. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Adverse Events at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
ABX-001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07231458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231458.